Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test

  • Chembio Diagnostics Inc CEMI submitted an Emergency Use Authorization (EUA) application to the FDA for the new DPP SARS-CoV-2 Antigen test.
  • The DPP SARS-CoV-2 Antigen test system has been designed to detect COVID-19 antigens in 20 minutes. 
  • See here Benzinga's Full FDA Calendar.
  • The DPP SARS-CoV-2 Antigen test system is now designed to use a minimally invasive nasal swab and be read visually or with a DPP Micro Reader or DPP Micro Reader 2 optical analyzer.
  • Chembio submitted a EUA application to the FDA for its DPP Respiratory Antigen Panel test system in September.
  • Related Link: Chembio Stock More Than Doubles On $28M Purchase Order For Its COVID Antigen Tests.
  • Price Action: CEMI shares are up 4.85% at $2.16 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!